LOGC Historical PE Ratio image   This LOGC PE ratio history page last updated 11/15/2022
LOGC Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/14/2022
2.06-0.18-0.72NA
Q2 2022
8/15/2022
0.52-0.15-0.60NA
Q1 2022
5/16/2022
0.43-0.20-0.80NA
Q4 2021
3/4/2022
0.65-0.28-1.12NA
Q3 2021
11/15/2021
3.52-0.31-1.24NA
Q2 2021
8/9/2021
4.29-0.33-1.32NA
Q1 2021
5/10/2021
4.66-0.32-1.28NA
Q4 2020
3/15/2021
8.18-0.19-0.76NA
Q3 2020
11/9/2020
5.70-0.34-1.36NA
Q2 2020
8/10/2020
8.26-0.35-1.40NA
Q1 2020
5/11/2020
6.78-0.41-1.64NA
Q4 2019
3/16/2020
4.06-0.51-2.04NA
Q3 2019
11/12/2019
9.55-0.48-1.92NA
Q2 2019
8/13/2019
9.50-0.45-1.80NA
Q1 2019
5/14/2019
14.02-0.34-1.36NA
Q4 2018
4/1/2019
9.77-0.41-1.64NA
Q3 2018
12/3/2018
14.51-4.03-16.12NA
LOGC PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/14/2022
2.06-0.18-0.81NA
Q2 2022
8/15/2022
0.52-0.15-0.94NA
Q1 2022
5/16/2022
0.43-0.20-1.12NA
Q4 2021
3/4/2022
0.65-0.28-1.24NA
Q3 2021
11/15/2021
3.52-0.31-1.15NA
Q2 2021
8/9/2021
4.29-0.33-1.18NA
Q1 2021
5/10/2021
4.66-0.32-1.20NA
Q4 2020
3/15/2021
8.18-0.19-1.29NA
Q3 2020
11/9/2020
5.70-0.34-1.61NA
Q2 2020
8/10/2020
8.26-0.35-1.75NA
Q1 2020
5/11/2020
6.78-0.41-1.85NA
Q4 2019
3/16/2020
4.06-0.51-1.78NA
Q3 2019
11/12/2019
9.55-0.48-1.68NA
Q2 2019
8/13/2019
9.50-0.45-5.23NA
Q1 2019
5/14/2019
14.02-0.34NANA
Q4 2018
4/1/2019
9.77-0.41NANA
Q3 2018
12/3/2018
14.51-4.03NANA
Quotes delayed 20 minutes

Email EnvelopeFree LOGC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
LogicBio Therapeutics (LOGC) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

LPCN PE Ratio History
LPTX PE Ratio History
LQDA PE Ratio History
LRMR PE Ratio History
LTRN PE Ratio History
LUMO PE Ratio History
LUNG PE Ratio History
LXRX PE Ratio History
LYEL PE Ratio History
LYRA PE Ratio History
How should the LOGC historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like LogicBio Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this LOGC Historical PE Ratio page.

What is the average historical PE for LOGC based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The LOGC historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for LOGC based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The LOGC historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the LOGC Historical PE Ratio information for LogicBio Therapeutics' stock. The average LOGC historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average LOGC historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this LOGC historical PE result, against the recent PE: when this page was posted on 11/14/2022, the most recent closing price for LOGC had been 2.06, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on LOGC or any other given stock, valuation analysis for LOGC can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate LogicBio Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for LOGC. Thanks for visiting, and the next time you need to research LOGC Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: FCAP Split History, LDOS DMA, MFRM Options Chain.

 

LOGC Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.